Related by context. All words. (Click for frequent words.) 91 Hemorrhagic Stroke caused 80 Cerebril TM 69 DG# compounds targeting 68 corneal transplant rejection 67 Crofelemer budesonide foam 67 candidates Azedra TM 67 Testosterone MDTS R 67 delayed onset CINV 66 novel orally inhaled 66 Completes Patient Enrollment 66 gastro intestinal inflammation 66 Combination REOLYSIN R 66 personalized cellular immunotherapy 66 CYT# potent vascular disrupting 65 Solazed TM 65 label Lipofen R 65 familial amyloidotic polyneuropathy FAP 65 Staphylococcus aureus Immune Globulin 65 Initiates Phase II 65 TRANSDUR ® 65 Phase IIb Trial 65 Completes Enrollment 65 acute radiation enteritis 65 Meets Primary Endpoint 65 pralatrexate injection folate analogue 65 Trial Evaluating 65 ELADUR ™ 65 oral Janus kinase 65 Initiates Enrollment 64 BCG refractory carcinoma 64 kidney urologic 64 * olmesartan medoxomil 64 TRANSDUR ™ 64 NASH Huntington 64 novel VDA molecule 64 individualized cellular immunotherapy 64 FOLOTYN ® 64 oral nucleoside analogue 64 XL# anticancer compounds 64 HYVISC ® treatment 64 oncolytic virus therapies 64 antiplatelet compound 64 acute onset CINV 64 Phase 2b Clinical Trial 64 registrational Phase 64 specific CCR9 antagonist 64 dependent kinase inhibitor 64 Vitrasert R 64 Provectus Pharmaceuticals specializes 64 candidate CRLX# 64 evaluating T DM1 64 Randomized Double blind 63 Onalta 63 Novel Oral 63 lexidronam injection 63 J Am Acad 63 sarcoma melanoma 63 Study Evaluating 63 Initiates Clinical Trial 63 Empatic ™ 63 PEGylated Fab fragment 63 Presents Positive 63 myocardial infarction ventricular fibrillation 63 Cancer Incidence Mortality 63 Neutrolin ® 63 By JENNIFER LEARN 63 Files IND 63 brand ciclesonide HFA 63 particularly SANCTURA XR 63 First Patient Enrolled 63 toenail onychomycosis 63 ATRA IV 63 6 sulfatase 63 candidate XP# 63 dasatinib Sprycel ® 63 non nucleoside inhibitor 63 Phase III Pivotal 63 MKC# MT 63 arthritis PsA 63 LymphoStat B belimumab 63 equine osteoarthritis marketed 63 J Antimicrob Chemother 63 HCV NS5B polymerase 63 oral prodrug 63 metastatic pancreatic 63 hyperphenylalaninemia HPA due 62 severe oral mucositis 62 SPL# Gel vaginal microbicide 62 cervical cancer precancerous 62 acyclovir Lauriad R 62 Commences Phase 62 Plaque Psoriasis 62 Proc Am Soc 62 allosteric modulator PAM 62 Empatic TM 62 evaluating tivozanib 62 INSPIRE Trial Phase III 62 albiglutide currently 62 FDA APPROVES 62 MKC# MKC# PP 62 Patient Enrollment 62 Advanced Renal Cell 62 Adjuvant Treatment 62 vaginally administered lidocaine 62 equine osteoarthritis 62 Randomized Double Blind 62 cardiac myosin activator omecamtiv 62 USP Tablets PEPCID 62 arsenic trioxide injection 62 AAG geldanamycin analog 62 Phase Ib IIa 62 Initiates Phase III 62 nasal decolonization 62 PROSTASCINT R 62 Omacetaxine 62 candidates Augment ™ 62 clinical trials Archexin 62 Phase 1b clinical trials 62 lintuzumab SGN 62 product platforms AZX# 62 atherothrombotic events 62 Malignant Melanoma 62 MT#/MEDI-# 62 dimebon latrepirdine 62 methylnaltrexone bromide 62 CYP#A# CYP#D# 62 Chronic Hepatitis C 62 Namenda Memantine HCl 62 Bayer HealthCare Onyx Pharmaceuticals 62 Brentuximab Vedotin SGN 62 Efficacy Results 62 Unigene nasal calcitonin 62 Achieves Primary Endpoint 62 BY WILLA J. 62 polyneuropathy HIV DSP 62 Aflibercept 62 Ceflatonin R 62 containing granisetron 62 essential thrombocythemia ET 62 Pruvel TM 62 IN PATIENTS WITH 62 delivers fluocinolone acetonide FA 62 induced macular edema 62 Advanced Melanoma 62 Zenvia ™ 62 ALTROPANE R 62 developing Bicifadine serotonin 62 Phase III Clinical Trial 62 allosteric modulator NAM 62 Budesonide foam crofelemer 62 Hypoactive Sexual Desire Disorder 62 urethral bulking agent 61 antibody MAb 61 colorectal bladder 61 hyperplasia BPH 61 called IntelliWrite ™ 61 read Palintologist 61 vitreoretinal disorders 61 Oral Calcitonin 61 5 HT3 antagonist 61 recombinant PSMA vaccine 61 Fludara ® 61 R Saizen R 61 ThermoDox ® clinical 61 Severe Sepsis 61 Xcytrin R 61 hypothyroidism hyperglycemia hypotension arrhythmihemorrhagic colitis development 61 Second Pivotal Phase 61 VEGFR2 inhibitor 61 mGluR2 positive 61 Double Blind Placebo 61 investigational humanized monoclonal antibody 61 known dihydropyrimidine dehydrogenase 61 Amigal TM 61 Phase #b/#a clinical 61 refractory chronic lymphocytic 61 MT# MEDI 61 Successfully Completes Phase 61 Pivotal Phase III 61 Patients Treated With 61 phase IIb clinical 61 somatostatin analog 61 cardiovascular disease autoimmune disorders 61 sapacitabine CYC# 61 forodesine purine nucleoside phosphorylase 61 sunitinib Sutent ® 61 Oral Fingolimod 61 oral ghrelin agonist 61 Prodarsan R 61 miconazole Lauriad R 61 NicVAX TM 61 opioid induced bowel dysfunction 61 R lenalidomide 61 Receives Orphan Drug Designation 61 Demonstrates Positive 61 Pooled Analysis 61 Patient Accrual 61 Telik logo TELINTRA 61 Epratuzumab 61 cervical vulvar 61 rALLy clinical trial 61 Custirsen 61 mGluR5 negative 61 unique alkylating agent 61 Initiates Phase 61 Frozen Shoulder syndrome Adhesive 61 virus HCV protease inhibitor 61 ADVANCE ILLUMINATE 61 recurrent metastatic ovarian cancer 61 Perifosine KRX 61 Pivotal Phase 61 Initiate Phase III 61 Wafer polifeprosan 61 JAK2 Inhibitor 61 triggers apoptosis programmed 61 tramiprosate Alzhemed TM 61 First Patient Dosed 61 ALN HPN 61 Recurrent Breast Cancer 61 SPRYCEL ® 61 Prolongs Survival 61 vapreotide acetate 61 orally inhaled migraine 61 Agonist MABA program 61 Hormone Refractory Prostate Cancer 61 Silodosin 61 Contrast Induced Nephropathy 61 Advaxis Phase 61 Syncria R 61 Randomized Clinical Trials 61 Amgen Neulasta R 61 includes TOLAMBA TM 61 systemic Phase 1b 61 PDX pralatrexate 61 PNP inhibitor 61 Arch Neurol 61 diarrhea predominant irritable 61 HIV AIDS neuropathic pain 61 Ovitrelle R Serostim 61 Lymphocytic 61 oropharyngeal candidiasis OPC 61 Non Alcoholic Steatohepatitis 61 Phase IIa Clinical Trial 61 targeted radiotherapeutic 61 includes Dideco CarboMedics 61 Initiated Phase 61 dextromethorphan quinidine 61 Complicated Skin 61 bevirimat Study 61 treatment naïve genotype 61 NS5B polymerase 61 Demonstrates Sustained 61 erlotinib Tarceva ® 61 common neurovascular complication 60 pharmacogenomic translational research 60 Alzheimer disease cognitive impairment 60 MEND CABG 60 Phase Ib II 60 inflammatory PDE 60 See WARNINGS 60 Antigen Specific 60 Crit Rev 60 Phase 2a Clinical Trial 60 RECORD1 60 Testosterone MDTS ® 60 candidate AQ4N 60 CCX# B 60 Hematology Molecular Pathology 60 RANK Ligand inhibitor 60 Granted Orphan Drug 60 AA Amyloidosis 60 Phase III multicenter 60 LungAlert TM 60 albiglutide 60 Randomized Phase III 60 Anthrax Toxin 60 BENLYSTA TM 60 FOLFOX6 chemotherapy regimen 60 CTA# Injection 60 P#X# antagonist 60 leukotriene pathway 60 GVAX ® 60 including eniluracil ADH 60 agonistic human 60 Teva Provides Update 60 TNF Tumor Necrosis Factor 60 post herpetic neuralgia PHN 60 PEGINTRON TM 60 EXECUTIVE SUMMARY II 60 bazedoxifene conjugated estrogens 60 R roscovitine CDK cyclin 60 Diabetic Macular Edema 60 evaluating picoplatin 60 SinuNase TM 60 Hsp# Inhibitor 60 Begins Dosing 60 oral mucositis OM 60 Cytogen marketed 60 lucinactant 60 CTAP# Capsules 60 Vitrasert ® 60 Ecallantide 60 Randomized Phase II 60 Anthracycline 60 Mg Usa 60 Vidofludimus 60 constipation OIC 60 Mylan Receives Approval 60 VIVITROL ® 60 GERD migraine headaches 60 delayed CINV 60 receptor tyrosine kinase inhibitor 60 plus Copegus R 60 3 registrational trial 60 OAB overactive bladder 60 lead Aganocide compound 60 Oral NKTR 60 cervix colon 60 chronically immunosuppressed solid 60 initiated Phase Ib 60 Controlled Study 60 Acute Exacerbations 60 Aplidin R 60 neuropathic pain spasticity 60 visit www.ncpc.org 60 trial evaluating PRX# 60 Nephrol Dial Transplant 60 DIRECT Trial 60 TNFerade ™ 60 AN# topical anti 60 PROGENSA R 60 Shows Promise Against 60 Submits NDA 60 vaginal lidocaine product 60 Telik Announces 60 MKC# 60 Soft Tissue Sarcoma 60 YOUR LOCAL ANIMAL SHELTER 60 Initiate Phase 60 Randomized Phase 60 cardiometabolic diseases Glucophage 60 accumulate preferentially 60 Staphylococcus aureus Polysaccharide Conjugate 60 Phase Ib clinical 60 transthyretin TTR mediated amyloidosis 60 approved incretin mimetic 60 novel antimitotic agent 60 IMPDH inhibitor 60 PEGINTRON REBETOL combination 60 Aeolus Pharmaceuticals Announces 60 Philadelphia Chromosome Positive 60 Treatment Shows Promise 60 BRIM2 60 Intravenous Human 60 AEG# 60 blood serum biomarkers 60 molecular imaging radiopharmaceutical 60 PANVAC VF 60 hepatitis C HCV 60 number NCT# ClinicalTrials.gov 60 include ColorectAlert TM 60 Catheter Associated 60 aldehyde dehydrogenase ALDH2 deficiency 60 CAPACITY trials 60 Pharmacokinetics PK 60 pan histone deacetylase 60 BRIM3 60 Genes Predict 60 antiangiogenesis therapies 60 cat dander allergy 60 diabetes hyperlipidemia 60 Seliciclib CYC# 60 QUADRAMET R 60 Kit CD# positive 60 TG MV 60 RELOVAIR ™ 60 ORACLE MS 60 Myocet 60 Dupuytren Disease 60 Curaxin CBLC# 60 Hosp Epidemiol 60 anti VEGF aptamer 59 treat male hypogonadism 59 relapsed MM 59 Personalized Immunotherapy 59 humanized interleukin 6 59 Elagolix 59 Phase IIb Clinical Trial 59 generation DACH Platinum 59 Volumex Daxor single 59 Phase 2a clinical 59 APEX PD 59 CCR9 antagonist 59 demonstrated antitumor activity 59 Systemic Sclerosis 59 See CLINICAL PHARMACOLOGY 59 samarium Sm 59 Xyfid TM 59 CYP#A# isoenzyme 59 miconazole Lauriad ® 59 syndrome overactive bladder 59 related CMV Retinitis 59 Phase Ib clinical trials 59 Selective Electrochemical Tumor Ablation 59 metabolism viral replication 59 cytomegalovirus CMV retinitis 59 rheumatoid arthritis RA psoriatic 59 dasatinib Sprycel 59 receiving chemoradiation therapy 59 Vidaza ® 59 pulmonology portfolio 59 LUX Lung 59 metastatic colorectal 59 Serostim ® 59 Commence Phase 59 Safinamide 59 REVIVE Diabetes 59 ovarian esophageal 59 RAS MAPK pathway 59 Metastatic Melanoma 59 symptomatic BPH 59 orally administered inhibitor 59 Invasive Fungal Infections 59 Idiopathic pulmonary fibrosis 59 Bosutinib 59 targeting miR 59 Primary Hypercholesterolemia 59 intravesical infusion therapy 59 Multicenter Phase 59 solid tumors ZYBRESTAT 59 Patients Suffering 59 2 methoxyestradiol 59 sorafenib tablets 59 simplex virus 59 TO AVOID PREGNANCY WHILE 59 milnacipran HCl 59 phase Ib clinical 59 investigational monoclonal antibody 59 Single Dose 59 treat dysmenorrhea 59 hypertrichosis occurred 59 About Positron Positron 59 Newly Diagnosed Multiple Myeloma 59 R sorafenib tablets 59 phase IIa clinical 59 phase III ACCLAIM 59 Elestrin ® 59 metastatic colorectal carcinoma 59 SoftScan ® 59 Arno Therapeutics 59 modified glutathione analog 59 Hemispherx flagship products 59 oral RSD# 59 Completes Dosing 59 Cloretazine ® 59 relapsing multiple sclerosis 59 keloid scarring 59 Intravenous CP 59 EOquin TM phase 59 evaluating carfilzomib 59 renal failure interstitial lung 59 Albuferon TM 59 Chronic Heart Failure 59 Adjuvant Chemotherapy 59 LHRH antagonists 59 relapsing remitting MS RRMS 59 PROVENGE ® 59 Rilonacept 59 HCV Protease Inhibitor 59 Phase III PREGNANT PROCHIEVE 59 Relapsed Refractory 59 malignant mesothelioma Alfacell 59 telomerase therapeutic 59 Presents Preclinical Data 59 PPI omeprazole 59 investigational immunotherapy 59 NEBIDO VANTAS SUPPRELIN LA 59 angiotensin analog 59 delivery polymer matrix 59 undergoing elective percutaneous 59 Zemiva TM 59 Phase III Trial 59 Receives Approvable Letter 59 PEGylated docetaxel 59 myelodysplastic myeloproliferative diseases 59 Bezielle 59 Epothilone D 59 Refractory Hodgkin Lymphoma 59 Bronchopulmonary Dysplasia 59 included exfoliative dermatitis 59 Inhalation Aerosol 59 cardiac sarcomere activators 59 evaluating mipomersen 59 anti botulism antibody 59 Phase 2b Trial 59 Renal Cell Carcinoma RCC 59 Dose Escalation 59 NU# direct 59 ALVESCO ® 59 Gentium Announces 59 Subgroup Analysis 59 non peptidic protease 59 Maximum Tolerated Dose MTD 59 Lipid Polymer Micelle LPM 59 evaluating intravenous picoplatin 59 Onalta TM 59 Limb Ischemia 59 IgG1 monoclonal antibody 59 Capsulitis 59 HIV distal sensory 59 assessing T DM1 59 ENABLE Phase 2 59 POSIDUR TM ELADUR TM 59 THAT ARE DIFFICULT TO 59 stage IIIb IV 59 CIMZIA ™ 59 Pemphigus Vulgaris 59 endometriosis ovarian cysts 59 class mGluR5 inhibitor 59 Pentacel R 59 Abiraterone Acetate 59 carcinoma mCRC 59 Entereg TM 59 Ridaforolimus 59 apricitabine ATC 59 Invasive pneumococcal disease 59 Qnexa TM 59 MEK Inhibitor 59 Demonstrates Efficacy 59 non alcoholic steatohepatitis 59 delta gamma agonist 59 Viread tenofovir disoproxil fumarate 59 PhotoPoint R 59 Therapy RecoveryRx TM 59 hepatitis C viral infection 59 Investigational Treatment 59 SW3d #,#-# Tex. Crim 59 Preclinical Study 59 Tyrosine Kinase Inhibitor 59 cisplatin gemcitabine 59 TRACON Pharmaceuticals Inc. 59 multi kinase inhibitor 59 eye socket ruptured 59 Cardiac Resynchronization 59 investigational oral inhibitor 59 glucocorticoid induced osteoporosis 59 hypoxia activated prodrug 59 topical non steroidal 59 introduced NEUGENE 59 Phase Ib Clinical Trial 59 GI motility disorders 59 phase IIb study 58 evaluate ZFP Therapeutic 58 EXPLORE Xa 58 ChromoCure develops 58 Suppository Hydrocortisone Acetate Rectal 58 oral calcitonin licensed 58 Prospective Randomized 58 treat musculoskeletal metabolic 58 Venous Thromboembolism 58 HeartMate ® 58 Ozarelix 58 CHAMPION PCI 58 PATHFINDER ® TRACER 58 antibody MT# 58 Luramist TM 58 INDEPENDENT SPORTS EDITOR 58 ExTRACT TIMI 58 adjuvant GIST 58 advanced metastatic renal 58 mecarbil 58 compound INCB# 58 coronary stent merged 58 Myocardial Infarction Study 58 HYVISC R 58 vinca alkaloid 58 postherpetic neuralgia PHN painful 58 manufactures minimally invasive 58 IMA# 58 Hedgehog Pathway Inhibitor 58 velafermin 58 TRANSFORMS 58 Treating Chronic 58 overactive bladder VANTAS R 58 biliary strictures produced 58 metastatic castration resistant 58 product Abreva ® 58 Staccato prochlorperazine 58 psoriatic arthritis PsA 58 TMC# C# 58 treat benign prostatic 58 metastatic androgen independent 58 Localized Prostate Cancer 58 ® lenalidomide 58 Immunomedics Announces 58 sodium thiosulfate STS 58 Iluvien ® 58 treatment naive genotype 58 Cutaneous T 58 rheumatoid arthritis osteoarthritis ankylosing 58 catheter occlusion 58 Endologix Powerlink System 58 II Clinical Trial 58 Shows Promising 58 Neulasta R 58 Hodgkin lymphoma HL 58 gastrointestinal stromal 58 Inflammatory Arthritis 58 oral picoplatin 58 Alvine Pharmaceuticals 58 Phase 2a Trial 58 commercializing therapeutic 58 SUPPRELIN R LA 58 cardiorenal disease 58 acetonide FA 58 Shows Efficacy 58 alfa 2a 58 monoclonal antibody IgG1 Mab 58 resistant hormone refractory 58 Biomerix Corporation 58 Multicenter Randomized 58 Completes Patient Enrolment 58 SinuNase ™ 58 Drug Shows Promise 58 oral dual endothelin 58 Enrolling Patients 58 TOFUTTI products 58 Paclitaxel Carboplatin 58 Diabetic Ulcers 58 ankylosing spondylitis AS 58 diabetic neuropathic pain 58 systemic anaplastic large 58 class anticancer quinolone 58 organ transplantation chronic 58 MelaFind R 58 Hospital Acquired Pneumonia 58 Therapeutic Vaccine 58 Albuferon albinterferon alfa 2b 58 Multiple Ascending Dose 58 dose escalation clinical 58 Daclizumab 58 occlusion PAO 58 SPEAR Study 58 Phase 1b clinical 58 Truvada tablets 58 active ankylosing spondylitis 58 Hemorrhagic Stroke 58 PI3K/Akt pathway inhibitor 58 product BioThrax ® 58 Pivotal Trial 58 IRX 2 58 Embosphere R 58 Traumatic Spinal Cord Injury 58 OTCBB URGP specialty 58 Confirmatory Phase 58 Aloprim TM allopurinol sodium 58 endoluminal stent graft 58 Early Relapsing Multiple 58 Dose Ranging Study 58 Slows Progression 58 diarrhea fatigue asthenia 58 Microplasmin 58 myelofibrosis polycythemia vera 58 Evoltra ® 58 Decompensated Heart Failure 58 mertansine 58 Heterozygous Familial Hypercholesterolemia 58 Inflammatory Diseases 58 pigmentary disorders 58 AKT inhibitor 58 Neuroendocrine Tumors 58 infectious diseases autoimmune diseases 58 Glufosfamide 58 candesartan cilexetil 58 INSEEC Schools 58 targeted immunotherapies 58 EnteroMedics proprietary neuroblocking technology 58 Atypical Hemolytic Uremic Syndrome 58 Bazedoxifene 58 steroid refractory GvHD 58 ALN TTR 58 juvenile firesetting 58 novel tubulin binding 58 metastatic malignant 58 humanized therapeutic 58 product Fentanyl TAIFUN 58 Val HeFT 58 oral transmucosal fentanyl citrate 58 Mg Uk 58 Severe VOD 58 Phase 2b clinical trials 58 vaginal candidiasis 58 invasive candidiasis 58 Eluting Stent 58 cell carcinoma RCC 58 psoriasis rheumatoid arthritis 58 CDK cyclin dependent 58 either acutely decompensated 58 ACAPODENE TM 58 Enrolls First 58 bile duct tumor 58 Fungal Infections 58 overt hepatic encephalopathy HE 58 Graft Versus Host 58 dermatology therapies 58 refractory cutaneous T 58 Submits Biologics License Application 58 evaluating REVLIMID 58 IND Filing 58 Immunotherapeutic 58 Vascular Disrupting Agent 58 Vicriviroc 58 R bendamustine hydrochloride 58 generation radiolabeled antibody 58 Sapacitabine 58 NAVISTAR R 58 Phase 2b Study 58 Phase III placebo controlled 58 interferon gamma 1b 58 EDEMA3 trial 58 selective androgen receptor modulator 58 Metastatic Prostate Cancer 58 ERYtech 58 SNT MC# 58 ORAL Solo 58 pelvic malignancies 58 controlled multicenter Phase 58 Dose Ranging 58 Warfarin Coumadin 58 Refractory Peripheral T 58 Vicinium TM 58 See CONTRAINDICATIONS 58 Ganite ® 58 Quinamed 58 R bortezomib 58 acute humoral rejection 58 Serious Infections 58 Charles Dullin School 58 rasagiline tablets 58 Mol Med 57 herpes zoster shingles 57 ® bortezomib 57 Dose Limiting Toxicity DLT 57 bevacizumab Avastin ® 57 rheumatoid arthritis psoriatic arthritis 57 grade cervical dysplasia 57 CEQ# 57 PRTX 57 TransVax ™ 57 LymphoStat B TM 57 interventional cardiologists electrophysiologists Cyril Beuzit head 57 HuMax TAC 57 Aztreonam lysine 57 ViaDerm hPTH #-# 57 Clinical Trial Results 57 Topline Results 57 PREGNANT PROCHIEVE ® 57 Placebo Controlled 57 endoscopic autofluorescence imaging 57 surgical adhesions 57 receiving INTRON 57 blinded randomized placebo controlled 57 MAGE A3 ASCI 57 Hypertensive adverse reactions 57 data management Clintrial 57 Sleep Disturbances 57 GW# [003] 57 ThermoDox R 57 AVASTIN 57 Besivance 57 Associated Adipose Redistribution 57 Nasdaq MSON designs 57 ERBITUX cetuximab 57 RH1 57 monoclonal antibody MAb 57 Pivotal Study 57 Cobalamin TM mediated 57 Dapagliflozin 57 interferon alpha IFN 57 multicenter Phase III 57 liposomal formulation 57 Nutra Pharma wholly owned 57 Unstable Angina 57 Ischemic Stroke 57 multicenter placebo controlled 57 Clinical Trial Evaluating 57 ovarian pancreatic 57 INTEGRILIN R eptifibatide Injection 57 Solesta ™ 57 Diamyd Medical Diamyd 57 folate analogue metabolic 57 Synta Announces 57 candidate REP# 57 Treatment Naive Patients 57 recurrent malignant glioma 57 Oracea TM 57 Inc. Amex KAL 57 cathepsin K inhibitor 57 injectable bulking agent 57 CIMZIA TM certolizumab pegol 57 Cardiotoxicity 57 pseudobulbar affect PBA 57 WX UK1 57 Initiates Phase 2b 57 ALN TTR# 57 Hepatitis C Infection 57 DRX# True Non 57 RISKS UNCERTAINTIES AND ASSUMPTIONS 57 Treatment Experienced 57 Pruvel ™ prulifloxacin 57 cytomegalovirus infection 57 evaluating Actimmune 57 complement inhibitor eculizumab 57 NPC 1C 57 non thiazolidinedione TZD 57 EchoCRT 57 SNT-MC#/idebenone 57 Pegloticase 57 Lipsovir R 57 pulmonary fungal infections 57 Preclinical Models 57 IMiDs ® compound 57 Alzhemed TM 57 urinary bladder wall 57 Myelodysplastic Syndrome MDS 57 Prednisone Against Refractory 57 CALGB # [002] 57 HuMax Wnt 57 Antitumor Activity 57 DVT prophylaxis cholesterol 57 AFREZZA TM 57 irinotecan cisplatin 57 Elacytarabine 57 Deforolimus 57 overactive bladder AA# 57 metastatic castrate resistant 57 HCD# [002] 57 ALISTA TM 57 STRIDE PD 57 Degarelix 57 developing calcitonin 57 opioid bowel dysfunction 57 Central Retinal Vein 57 Chronic Myeloid Leukemia 57 Xeloda ® 57 Preclinical Efficacy 57 Relapsing Remitting Multiple Sclerosis 57 NEUPOGEN R 57 IMiDs ® 57 including acne photodamage 57 Colorectal Cancer CRC 57 Previously Treated 57 IL# PE#QQR 57 Non Alcoholic Fatty 57 GTC recombinant form 57 IIa Clinical Trial 57 Humanized Anti 57 Receives CE Marking 57 Bucindolol Based 57 PET FROM 57 NASDAQ MSON developer 57 Adjuvant Therapy 57 Relapsing Multiple Sclerosis 57 Combivir Kivexa 57 FASEB J. 57 Nexavar ® 57 PROACT Phase 2 57 Clevudine 57 recurrent NSCLC 57 Phase IIa clinical 57 oral JAK#/JAK# inhibitor 57 organ transplant rejection 57 Sezary syndrome 57 initiate multicenter 57 including cyclosporine methotrexate 57 randomized controlled multicenter 57 Traficet EN 57 Nicotine Vaccine 57 Phase 1b Clinical Trial 57 Prochymal TM 57 Thromboembolism 57 investigational HCV polymerase 57 Bronchiectasis 57 Archexin 57 Myelofibrosis 57 PEGylated interferon beta 1a 57 VICTOR E3 57 benign prostatic hyperplasia enlarged 57 ISTODAX ® 57 Diabetic Macular Edema DME 57 nilotinib Tasigna ® 57 controlled dose escalation 57 Randomized Double Blind Placebo 57 Licenses Novel 57 MCSP respectively 57 HDAC Inhibitor 57 worsening thrombocytopenia 57 Pulmonary Arterial Hypertension 57 multicenter multinational 57 Teplizumab 57 vaccines oncolytic virus 57 VISICOL R 57 novel therapeutic antibodies 57 acadesine 57 Talabostat 57 HQK 57 NDA Submission 57 GREATER HAMILTON 'S 57 Recurrent Glioblastoma 57 refractory NSCLC 57 damage cirrhosis liver 57 Improves Outcomes 57 Naive Patients 57 RE MODEL 57 Left Ventricular Hypertrophy 57 cutaneous T 57 REUNITE FOR 57 TOCOSOL Camptothecin 57 EURONEXT SAN 57 recurrent glioblastoma multiforme 57 Kidney Int 57 Ribavirin causes 57 venous thromboembolic events 57 Anti Bacterial Envelope 57 Dementia Related Psychosis 57 Uterine Cancer 57 Drug Prevents 57 dyskinesia PD LID 57 Tanespimycin 57 Breast Cancer Recurrence 57 Anti Tumor Activity 57 Genaera Corporation 57 SOLTAMOX TM tamoxifen citrate 57 Juvenile Idiopathic Arthritis 57 Sorafenib HCC Assessment 57 Cortoss TM 57 Epidermal Growth Factor Receptor 57 thalidomide Thalomid 57 Septin9 biomarker 57 GATTEX TM 57 Evalve MitraClip R 57 surgical prophylaxis 57 docetaxel Taxotere ® 57 Biological Therapy 57 GTC recombinant human 57 interferon beta 1a infertility 57 Coadministration 57 Glioblastoma Multiforme 57 MGd 57 Injectable Suspension 57 Syndax Pharmaceuticals Inc. 57 Ischemic 56 systemic immunosuppressive drugs 56 HGS ETR1 mapatumumab 56 Sirolimus eluting Coronary Stent 56 Renal Cancer 56 TM pralatrexate injection 56 Controlled Trial 56 Arch Dis Child 56 Clostridium difficile Infection 56 negative allosteric modulator 56 refractory metastatic colorectal cancer 56 J Rheumatol 56 Friedreich Ataxia FRDA 56 Paroxysmal Nocturnal Hemoglobinuria PNH 56 refractory gout 56 lomitapide 56 Eculizumab 56 EQUATE OB 56 INS# [001] 56 pancreas esophagus 56 Dural Regeneration Matrix 56 adalimumab Humira 56 FACTIVE ® 56 FUSILEV enhances 56 novel emulsion formulation 56 trademarks Vitrasert R 56 intravenous RSD# 56 AACR IASLC Joint 56 % uracil topical 56 Systemic lupus erythematosus SLE 56 Annamycin 56 Chronic lymphocytic leukemia 56 PF # [002] 56 oral ridaforolimus 56 Gabapentin GR TM 56 designated HVTN 56 Callisto initiated 56 Romidepsin 56 pan BCR ABL 56 External Beam 56 Acute Myeloid Leukaemia AML 56 evaluating pirfenidone 56 hypereosinophilic syndrome 56 Therapy Improves 56 REVELATION ® Series 56 Hepatocellular Carcinoma HCC 56 Tesetaxel 56 metformin accumulation